| scholarly article | Q13442814 |
| P2093 | author name string | Muhammad Wasif Saif | |
| Danielle Detelich | |||
| Martin D Goodman | |||
| Sarah McPartland | |||
| P2860 | cites work | Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer | Q84768414 |
| Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial | Q87416761 | ||
| Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy | Q94679292 | ||
| The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale | Q33366660 | ||
| Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study | Q33405507 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study | Q33987300 | ||
| Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases | Q34003396 | ||
| Clinical delivery system for intraperitoneal hyperthermic chemotherapy. | Q34268781 | ||
| Peritonectomy procedures | Q34316366 | ||
| Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer | Q34390124 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. | Q34543902 | ||
| Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma | Q34562049 | ||
| Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy | Q34574200 | ||
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer | Q34590724 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620678 | ||
| Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy | Q34690528 | ||
| The cellular and molecular basis of hyperthermia | Q34721242 | ||
| Pharmacokinetics of intraperitoneal mitomycin C | Q35563276 | ||
| Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer | Q35837795 | ||
| Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy | Q36040207 | ||
| Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer | Q36151519 | ||
| Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy | Q36421715 | ||
| Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. | Q36571925 | ||
| Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma | Q36686192 | ||
| A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers | Q36989557 | ||
| Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. | Q37252019 | ||
| Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients | Q37266227 | ||
| Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei | Q37413266 | ||
| A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin | Q37478215 | ||
| A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy | Q37821289 | ||
| Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity | Q37895575 | ||
| Management of peritoneal carcinomatosis from colorectal cancer | Q37910396 | ||
| The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. | Q38201470 | ||
| Transport of Model Compounds across the Peritoneal Membrane in the Rat | Q39229778 | ||
| Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer | Q79150738 | ||
| Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | Q79467684 | ||
| Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma | Q80325049 | ||
| Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group | Q80428523 | ||
| Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients | Q80608554 | ||
| Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma | Q80980814 | ||
| Long-term survival of peritoneal carcinomatosis of colorectal origin | Q81645274 | ||
| Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer | Q81800767 | ||
| Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms | Q81827050 | ||
| Significance of lymph node metastasis in patients with colorectal cancer peritoneal carcinomatosis | Q83764549 | ||
| Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study | Q39928697 | ||
| Recent patterns in gastric cancer: a global overview | Q39985871 | ||
| Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial | Q40332575 | ||
| Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma | Q41134416 | ||
| Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology | Q41146005 | ||
| Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. | Q41649404 | ||
| Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. | Q42655076 | ||
| Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. | Q43064315 | ||
| Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. | Q43130795 | ||
| Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery | Q43288249 | ||
| Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients | Q43421690 | ||
| Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei | Q43548703 | ||
| Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy | Q43587312 | ||
| Peritoneal mesothelioma--incidence and etiology | Q43678230 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. | Q43703526 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. | Q43765205 | ||
| A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. | Q43847427 | ||
| Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution | Q43910359 | ||
| Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. | Q43932503 | ||
| Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer | Q44254193 | ||
| A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery | Q44376048 | ||
| Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study | Q46147063 | ||
| Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis | Q46463103 | ||
| Lymph node metastases in diffuse malignant peritoneal mesothelioma. | Q46599379 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. | Q50788596 | ||
| Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | Q51301047 | ||
| Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. | Q52540062 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. | Q53286355 | ||
| Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. | Q53571926 | ||
| Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. | Q53593898 | ||
| Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion | Q61794224 | ||
| Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei | Q61848914 | ||
| Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study | Q64046989 | ||
| Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies | Q68353048 | ||
| Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C | Q71600161 | ||
| Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer | Q72493614 | ||
| Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy | Q73327577 | ||
| Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique | Q73327596 | ||
| Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study | Q73368601 | ||
| Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases | Q73712914 | ||
| The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites | Q73790208 | ||
| Prospective trial for the treatment of malignant peritoneal mesothelioma | Q74625291 | ||
| Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy | Q75351687 | ||
| Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer | Q77887644 | ||
| Determinants of paclitaxel penetration and accumulation in human solid tumor | Q78016374 | ||
| Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma | Q78170268 | ||
| Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures | Q79121171 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 45-57 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy | |
| P478 | volume | 7 |
| Q64098751 | A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy |
| Q92140598 | Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review |
| Q64240258 | Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization |
| Q40967674 | Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation |
| Q89849951 | Increased Temperature Facilitates Adeno-Associated Virus Vector Transduction of Colorectal Cancer Cell Lines in a Manner Dependent on Heat Shock Protein Signature |
| Q39129504 | Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle |
| Q88718086 | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| Q39246331 | Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. |
| Q92617881 | Pharmacokinetic problems in peritoneal drug administration: an update after 20 years |
| Q92764306 | Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework |
| Q92381922 | Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018 |
| Q38731251 | Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. |
| Q61795888 | Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review |
| Q55663308 | Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. |
Search more.